Corinne Menn, DOMenopause and survivorship care

Menopause After Breast Cancer: Managing Symptoms Safely

Cancer treatment can bring menopause on suddenly, and endocrine therapy can make symptoms stronger. Here are the options that fit a survivor's life.

Survivorship7 min readPublished Reviewed

Key takeaways

  • Chemotherapy, ovarian suppression, surgery and endocrine therapy can all cause or intensify menopause symptoms.
  • Systemic hormone therapy is generally not recommended after breast cancer, but several nonhormone options work.
  • Some antidepressants interfere with tamoxifen, so medicine choice matters.
  • For vaginal symptoms, nonhormone treatments come first; low-dose vaginal estrogen may be considered with your oncologist.

For many breast cancer survivors, menopause doesn't arrive gradually. It can start abruptly with chemotherapy, ovarian suppression or surgery to remove the ovaries. Endocrine therapies such as tamoxifen and aromatase inhibitors, which many women take for five years or more, can make hot flashes, vaginal dryness and joint aches worse.

Dr. Menn knows this transition from both sides: as an OB/GYN who treats it, and as a long-term breast cancer survivor who went through premature menopause herself. The good news is that survivors have more evidence-based options than they're often told.

Why symptoms can be stronger

A sudden drop in estrogen tends to cause more intense symptoms than the gradual decline of a natural menopause. Aromatase inhibitors lower estrogen even further, and tamoxifen commonly causes hot flashes. Symptoms matter beyond comfort: they are one of the reasons women stop endocrine therapy early, which can affect cancer outcomes. Treating them is part of cancer care.

Hot flashes and night sweats without hormones

For women with a history of breast cancer, systemic hormone therapy is generally not recommended.[1] The Menopause Society's 2023 nonhormone position statement recommends several alternatives with good evidence:[2]

  • CBT and clinical hypnosis. Drug-free, with no interactions.
  • SSRIs and SNRIs. Certain antidepressants, such as venlafaxine, reduce hot flashes. If you take tamoxifen, paroxetine and fluoxetine are usually avoided because they can interfere with how tamoxifen is activated.
  • Gabapentin. Often helpful when night sweats are disrupting sleep. Drowsiness and dizziness are common at first.
  • Oxybutynin. Effective in studies, though its side effects need weighing, especially for older women.
  • Fezolinetant. A newer nonhormone medicine that acts on the brain's temperature-control center. In a large trial it reduced how often hot flashes happened compared with placebo.[3] The main trials did not focus on breast cancer survivors, so discuss it with your oncologist, and expect liver blood tests as its label requires.

Vaginal dryness and painful sex

Vaginal and urinary symptoms are common after cancer treatment, especially on aromatase inhibitors, and they usually don't get better on their own. Vaginal moisturizers used regularly and lubricants for sex are the first step.[4] Pelvic floor physical therapy and vaginal dilators help when pain has led to muscle tension.

If those aren't enough, ACOG's clinical consensus says low-dose vaginal estrogen may be considered after a discussion of risks and benefits, including for women taking tamoxifen. For women on aromatase inhibitors, the decision should be shared among the patient, her gynecologist and her oncologist.[5] Oral ospemifene isn't recommended for survivors because it hasn't been studied enough in this group.[4]

The question isn't only “is it safe?” It's “what is safe enough for me, given my cancer, my treatment and how much this affects my life?” That answer is personal, and it belongs to you and your team together.

Bones, heart and the long view

Early menopause and aromatase inhibitors can both speed up bone loss. Your oncology team may recommend bone density testing. Getting enough calcium, mainly from food, and enough vitamin D, along with strength and balance exercise, supports bone health.[6] Heart health deserves attention too: blood pressure, cholesterol and blood sugar checks with your primary care doctor.

Building a plan with your oncology team

Bring your cancer type and receptor status, the treatments you've had, your current endocrine therapy, and a list of every medicine and supplement. Name the one or two symptoms that bother you most. A menopause plan for a survivor should always be written to share with the oncologist, so everyone is working from the same page.

Finally, give yourself time. Many treatments take several weeks to show their full effect, and it's common to try more than one before finding the right fit. Keeping a simple symptom diary makes it easier to judge what is helping. And if a symptom is making it hard to continue endocrine therapy, say so early: there is almost always something else to try.

When to see a doctor

Tell your oncology team about symptoms that make it hard to stay on endocrine therapy. Don't stop a prescribed cancer medicine without talking to them. Seek prompt care for a new breast lump, bone pain that doesn't go away, or unexplained bleeding.

Sources

  1. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. View source (opens in a new tab)
  2. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. View source (opens in a new tab)
  3. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. View source (opens in a new tab)
  4. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. View source (opens in a new tab)
  5. American College of Obstetricians and Gynecologists. Treatment of urogenital symptoms in individuals with a history of estrogen-dependent breast cancer. Clinical Consensus No. 2. Obstet Gynecol. 2021;138(6):950-960. View source (opens in a new tab)
  6. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973-997. View source (opens in a new tab)

Corinne Menn, DO, FACOG, MSCP

Board-certified OB/GYN and Menopause Society Certified Practitioner. Breast cancer survivor of more than 20 years and BRCA carrier.

About Dr. Menn  Editorial policy

This article is general education for adults and is not a substitute for personal medical advice. If you have a medical emergency, call 911.

Related articles